Skip to main content
Jamile Shammo, MD, Hematology, Chicago, IL, Rush Oak Park Hospital

JamileShammoMD, FASCP, FACP

Hematology • Chicago, IL

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Professor of Medicine Division of Hematology Oncology Northwestern University

Join to view full profile

Dr. Shammo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Shammo's full profile

Already have an account?

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 1996 - 1999
  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1991 - 1995
  • University of Chicago (NorthShore)
    University of Chicago (NorthShore)Residency, Pathology-Anatomic and Clinical, 1988 - 1991
  • University of Aleppo Faculty of Medicine
    University of Aleppo Faculty of MedicineClass of 1985

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1988 - 2026
  • American Board of Internal Medicine Hematology
  • American Board of Pathology Anatomic Pathology & Clinical Pathology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    Jamile M. Shammo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US
    Jamile M. Shammo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • A Novel Patient Reported Outcome Instrument Assessing the Symptoms of Paroxysmal Nocturnal Hemoglobinuria
    Jamile M. Shammo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies 
    60th American Society of Hematology Annual Meeting - 11/30/2018

Authored Content

  • Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria with EculizumabOctober 2017

Press Mentions

  • ASH Announces Executive Committee Election Results, New Clinical Practice Guidelines, and More
    ASH Announces Executive Committee Election Results, New Clinical Practice Guidelines, and MoreNovember 5th, 2020
  • Diagnosis of Myelodysplastic Syndrome
    Diagnosis of Myelodysplastic SyndromeJanuary 29th, 2020
  • Repurposed Drug Gives Woman with Cancer the Gift of Life
    Repurposed Drug Gives Woman with Cancer the Gift of LifeJuly 1st, 2018
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. Jamile Shammo, Dr. Jamile Shammo, MD, Dr. J Shammo